Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 361

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 361
---
 (15 | ) |
| Amounts paid on lease liabilities                      |     |      |     |       (188 | ) |     |       (178 | ) |     |       (112 | ) |
| Repayment from Government loan                         |     |   16 |     |          – |   |     |          – |   |     |       (103 | ) |
| Share issues including warrants, net of costs          |     |   14 |     |     10,427 |   |     |        243 |   |     |      9,035 |   |
| Net cash generated from financing activities           |     |      |     |     10,226 |   |     |         47 |   |     |      8,805 |   |
| Net increase/(decrease) in cash and cash equivalents   |     |      |     |      3,135 |   |     |     (7,221 | ) |     |      2,519 |   |
| Cash and cash equivalents at beginning of year         |     |      |     |      2,836 |   |     |     10,057 |   |     |      7,546 |   |
| Exchange (losses)/gains on cash and cash equivalents   |     |      |     |          – |   |     |          – |   |     |         (8 | ) |
| Cash and cash equivalents at end of year               |     |   14 |     |      5,971 |   |     |      2,836 |   |     |     10,057 |   |

The notes form an integral
part of these consolidated financial statements.

| F-27 |

Consolidated
statements of changes in equity

For the year ended 31 December

|                                                       |     |  Note |     | Share capital £’000 |     | Share premium £’000 |   |     |        Merger 
 reserve £’000 |     | Warrant 
 reserve 
   £’000 |     | Accumulated deficit £’000 |   |     | Total equity £’000 |   |
| At 1 January 2023                                     |     |       |     |               1,108 |     |              83,667 |   |     |        53,003 |     |     720 |     |                  (135,336 | ) |     |              3